NIMS Medical Genetics department in Hyderabad offers cutting-edge diagnostic and therapeutic services for rare genetic ...

Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

The Amsterdam-based company recently received IVDR certification for other tests including one for phenylketonuria.

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

协和医生说协和科普“渐冻人”“月亮的孩子”“睡美人综合症”“瓷娃娃”……这些听起来或美丽或梦幻的名字背后，其实是一类严重危害健康的疾病——罕见病。在罕见病的综合治疗领域，营养管理发挥着不可忽视的作用。今天，北京协和医院临床营养科专家就来带您了解关于罕 ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

Reports Q4 revenue $747M, consensus $711.05M. “Our operational transformation and strong financial execution in 2024 is the first step in ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” ...